These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 27959701)

  • 1. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
    Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
    N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
    Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
    Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
    N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Terrin ML; Moore RD; Dover GJ; Barton FB; Eckert SV; McMahon RP; Bonds DR
    N Engl J Med; 1995 May; 332(20):1317-22. PubMed ID: 7715639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
    Delgado J; Voltz C; Stain M; Lapveteläinen T; Urach S; Lähteenvuo J; Penttilä K; Gisselbrecht C; Enzmann H; Pignatti F
    Hemasphere; 2021 Jul; 5(7):e604. PubMed ID: 34235401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
    Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
    N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Biemond BJ; Tombak A; Kilinc Y; Al-Khabori M; Abboud M; Nafea M; Inati A; Wali Y; Kristensen J; Kowalski J; Donnelly E; Ohd J;
    Lancet Haematol; 2021 May; 8(5):e334-e343. PubMed ID: 33894169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
    Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
    SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
    Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
    Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
    Sy SKB; Tanaka C; Grosch K
    Clin Pharmacokinet; 2023 Feb; 62(2):249-266. PubMed ID: 36529836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crizanlizumab: First Approval.
    Blair HA
    Drugs; 2020 Jan; 80(1):79-84. PubMed ID: 31933169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnesium for treating sickle cell disease.
    Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment.
    Man Y; Goreke U; Kucukal E; Hill A; An R; Liu S; Bode A; Solis-Fuentes A; Nayak LV; Little JA; Gurkan UA
    Blood Cells Mol Dis; 2020 Jul; 83():102424. PubMed ID: 32208292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical evaluation of crizanlizumab for the treatment of sickle cell disease.
    Karki NR; Saunders K; Kutlar A
    Expert Rev Hematol; 2022 Jan; 15(1):5-13. PubMed ID: 34942078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
    Stevens DL; Hix M; Gildon BL
    J Pharm Technol; 2021 Aug; 37(4):209-215. PubMed ID: 34752581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 49.